Hims & Hers Health (NYSE:HIMS) Stock Price Down 2.4% - Here's Why

Key Points

• Hims & Hers Health shares dropped 2.4% on Friday, trading as low as $46.93, with significantly reduced trading volume, falling 68% from average levels.
• Several analysts have rated Hims & Hers Health stock with a mixed outlook, resulting in a consensus rating of "Reduce" and an average price target of $38.92.
• Despite a revenue increase of 72.6% year-over-year, the company missed earnings expectations, reporting $0.17 EPS, below the consensus of $0.18.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) fell 2.4% on Friday . The stock traded as low as $46.93 and last traded at $46.96. 10,500,375 shares were traded during mid-day trading, a decline of 68% from the average session volume of 33,110,566 shares. The stock had previously closed at $48.11.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HIMS. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Truist Financial lowered their price objective on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research report on Monday, August 18th. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research note on Monday, June 23rd. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Stock Up 0.6%

The firm has a market cap of $10.94 billion, a P/E ratio of 60.49, a price-to-earnings-growth ratio of 3.00 and a beta of 2.14. The stock's 50 day simple moving average is $50.05 and its 200 day simple moving average is $45.48. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the transaction, the chief financial officer directly owned 63,222 shares of the company's stock, valued at $2,987,239.50. The trade was a 26.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the transaction, the insider directly owned 169,940 shares in the company, valued at $9,105,385.20. This represents a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,390,328 shares of company stock valued at $71,468,298 over the last quarter. 13.71% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in HIMS. Virtus Advisers LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth about $26,000. Quaker Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth about $29,000. Bessemer Group Inc. lifted its holdings in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health during the first quarter valued at about $30,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after purchasing an additional 600 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.